Home The Word Brain	My Amedeo FAQ Privacy About
	Hanzi Hunter Learning 500 Chinese characters in 30 days is possible. Abstract • About

Prostate Cancer

Free Subscription Articles published in J Natl Cancer Inst Retrieve available abstracts of 46 articles: HTML format

Single Articles

March 2026
1. PALLER CJ, Wei S, Schumacher M, Rabizadeh D, et al
   Divergent effects of PLA2G7 on prostate cancer biochemical recurrence in european American and african American men.
   J Natl Cancer Inst. 2026 Mar 10:djag036. doi: 10.1093.
   PubMed     Abstract available
   
   
   
2. BOSLAND MC
   RE: Prostate cancer clinicopathological presentation in South-East Africa during the 2010 decade.
   J Natl Cancer Inst. 2026 Mar 7:djag059. doi: 10.1093.
   PubMed    
   
   
   
3. LU-YAO G, Nikita N, Keith SW, Gandhi K, et al
   Risk of fracture following androgen receptor pathway inhibitors in men with advanced prostate cancer.
   J Natl Cancer Inst. 2026 Mar 7:djag061. doi: 10.1093.
   PubMed     Abstract available
   
   
   February 2026
4. FISCHER MP, Alena M, Braun A, Kraft J, et al
   Polygenic risk scores for pre-MRI risk stratification in men with clinically suspected prostate cancer.
   J Natl Cancer Inst. 2026 Feb 2:djag027. doi: 10.1093.
   PubMed     Abstract available
   
   
   January 2026
5. DA SILVA M, Fritz J, Elhakeem A, Jochems SHJ, et al
   Weight trajectories throughout adulthood and prostate cancer incidence, aggressiveness, and death in 258,494 men.
   J Natl Cancer Inst. 2026 Jan 23:djag014. doi: 10.1093.
   PubMed     Abstract available
   
   
   
6. WESTVOLD SJ, Long JB, Fan J, Kc M, et al
   Cardiovascular risk in long-term survivors of breast, prostate, colon, and rectal cancer.
   J Natl Cancer Inst. 2026;118:130-140.
   PubMed     Abstract available
   
   
   
7. SCUDERI S, Tin AL, Marra G, Bianchi L, et al
   Assessing the oncologic risk when systematic and multiparametric magnetic resonance imaging-targeted prostate biopsy grade groups are discordant.
   J Natl Cancer Inst. 2026;118:76-84.
   PubMed     Abstract available
   
   
   December 2025
8. SPAUR M, Koutros S, Hurwitz LM, Manley CK, et al
   Drinking water nitrate, disinfection byproducts, and prostate cancer incidence in the Agricultural Health Study.
   J Natl Cancer Inst. 2025 Dec 5:djaf350. doi: 10.1093.
   PubMed     Abstract available
   
   
   
9. SCHENK JM, Gulati R, Beatty SJ, Plymate S, et al
   Reduced adipose tissue with limited loss of lean mass after weight loss: results from the Prostate Cancer Active Lifestyle Study.
   J Natl Cancer Inst. 2025;117:2682-2686.
   PubMed     Abstract available
   
   
   November 2025
10. DE FERIA CARDET RE, Goodall S, Laba TL, Haas M, et al
    What matters to society when making decisions about reimbursing drugs for prostate cancer: a discrete choice experiment.
    J Natl Cancer Inst. 2025 Nov 3:djaf315. doi: 10.1093.
    PubMed     Abstract available
    
    
    
11. VO JB, Brown DW, Buller ID, Shing JZ, et al
    Associations of self-identified race and ethnicity and genetic ancestry with mortality among cancer survivors.
    J Natl Cancer Inst. 2025;117:2382-2387.
    PubMed     Abstract available
    
    
    September 2025
12. VERTOSICK EA, Vickers A, Dahlin A, Ulmert D, et al
    Prostate-specific antigen levels at age 60 and lifetime risk of lethal prostate cancer.
    J Natl Cancer Inst. 2025 Sep 19:djaf271. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2025
13. QIAN Z, Korn S, Zurl H, Stelzl D, et al
    Active surveillance for low-risk prostate cancer: long-term utilization and outcomes among black men.
    J Natl Cancer Inst. 2025 Aug 14:djaf224. doi: 10.1093.
    PubMed     Abstract available
    
    
    
14. MAKAROV DV, Thomas JK, Ciprut S, Rivera AJ, et al
    Prostate Cancer Imaging Stewardship: a multi-modal, physician-centered intervention for guideline-concordant imaging.
    J Natl Cancer Inst. 2025 Aug 11:djaf210. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2025
15. 
    Correction to: The association of where patients with prostate cancer live and receive care on racial treatment inequities.
    J Natl Cancer Inst. 2025 Jun 26:djaf148. doi: 10.1093.
    PubMed    
    
    
    
16. 
    Correction to: The association of where patients with prostate cancer live and receive care on racial treatment inequities.
    J Natl Cancer Inst. 2025 Jun 13:djaf142. doi: 10.1093.
    PubMed    
    
    
    
17. SCILIPOTI P, Garmo H, Gedeborg R, Robinson D, et al
    Incidence and prognostic implications of prostate-specific antigen persistence and relapse after radical prostatectomy: population-based study.
    J Natl Cancer Inst. 2025;117:1142-1150.
    PubMed     Abstract available
    
    
    May 2025
18. CHEN F, Paik A, Sheng X, Cheng I, et al
    Risk of aggressive prostate cancer with successive generations in the U.S. among Latino men.
    J Natl Cancer Inst. 2025 May 27:djaf119. doi: 10.1093.
    PubMed     Abstract available
    
    
    
19. PATRICK SM, Ombuki WM, Ndambuki J, Oyaro MO, et al
    Prostate cancer clinicopathological presentation in South-East Africa during the 2010 decade.
    J Natl Cancer Inst. 2025 May 9:djaf117. doi: 10.1093.
    PubMed     Abstract available
    
    
    
20. MCWILLIAM A, Marshall D, Kerns SL, Barnett GC, et al
    Association of radiation-induced normal tissue toxicity with a high genetic risk for rheumatoid arthritis.
    J Natl Cancer Inst. 2025;117:1018-1026.
    PubMed     Abstract available
    
    
    February 2025
21. SEKAR RR, Zebib L, Stensland KD, Herrel LA, et al
    Structural inequities in the availability of prostate cancer clinical trial opportunities.
    J Natl Cancer Inst. 2025 Feb 26:djaf047. doi: 10.1093.
    PubMed     Abstract available
    
    
    January 2025
22. TOSOIAN JJ
    Active surveillance for prostate cancer: How active is too active?
    J Natl Cancer Inst. 2025 Jan 27:djae342. doi: 10.1093.
    PubMed    
    
    
    
23. MEZGER NCS, Seraphin TP, Balle R, Griesel M, et al
    NCCN guideline-concordant cancer care in sub-Saharan Africa: a population-based multicountry study of 5 cancers.
    J Natl Cancer Inst. 2025;117:120-133.
    PubMed     Abstract available
    
    
    
24. GOGLIA AG, Alshalalfa M, Khan A, Isakov DR, et al
    Pan-cancer genomic analysis reveals FOXA1 amplification is associated with adverse outcomes in non-small cell lung, prostate, and breast cancers.
    J Natl Cancer Inst. 2025;117:188-197.
    PubMed     Abstract available
    
    
    November 2024
25. HAMMARLUND N, Holt SK, Etzioni R, Morehead D, et al
    The Association of Where Patients with Prostate Cancer Live and Receive Care on Racial Treatment Inequities.
    J Natl Cancer Inst. 2024 Nov 20:djae302. doi: 10.1093.
    PubMed     Abstract available
    
    
    
26. ZHAO Y, Gulati R, Yang Z, Newcomb L, et al
    Projected Outcomes of Reduced-Biopsy Management of Grade Group 1 Prostate Cancer: Implications for Relabeling.
    J Natl Cancer Inst. 2024 Nov 20:djae296. doi: 10.1093.
    PubMed     Abstract available
    
    
    October 2024
27. COOPERBERG MR, Braun AE, Berlin A, Kibel AS, et al
    When is prostate cancer really cancer?
    J Natl Cancer Inst. 2024 Oct 1:djae200. doi: 10.1093.
    PubMed     Abstract available
    
    
    
28. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1675-1682.
    PubMed     Abstract available
    
    
    
29. LIU S, Rivero SL, Zhang B, Shen K, et al
    BATF-dependent Th17 cells act through the IL-23R pathway to promote prostate adenocarcinoma initiation and progression.
    J Natl Cancer Inst. 2024;116:1598-1611.
    PubMed     Abstract available
    
    
    September 2024
30. EL KHOURY CJ, Freedland SJ, Gandhi K, Keith SW, et al
    Disparities in the Utilization of MRI for Prostate Cancer Detection: A Population-Based Study.
    J Natl Cancer Inst. 2024 Sep 23:djae234. doi: 10.1093.
    PubMed     Abstract available
    
    
    August 2024
31. KATKI HA, Prorok PC, Castle PE, Minasian LM, et al
    Increasing power in screening trials by testing control-arm specimens: application to multicancer detection screening.
    J Natl Cancer Inst. 2024;116:1280-1287.
    PubMed     Abstract available
    
    
    July 2024
32. FARAJ KS, Oerline M, Kaufman SR, Dall C, et al
    Adverse events in men with advanced prostate cancer treated with androgen biosynthesis inhibitors and androgen receptor inhibitors.
    J Natl Cancer Inst. 2024 Jul 25:djae155. doi: 10.1093.
    PubMed     Abstract available
    
    
    June 2024
33. DING CC, Tony Su Z, Erak E, DePaula Oliveira L, et al
    Predicting prostate cancer grade reclassification on active surveillance using a deep Learning-Based grading algorithm.
    J Natl Cancer Inst. 2024 Jun 18:djae139. doi: 10.1093.
    PubMed     Abstract available
    
    
    May 2024
34. BJORNEBO L, Razdan S, Discacciati A, Palsdottir T, et al
    Prostate Cancer Incidence and Mortality in Men Exposed to alpha1-Adrenoceptor Antagonists.
    J Natl Cancer Inst. 2024 May 8:djae108. doi: 10.1093.
    PubMed     Abstract available
    
    
    February 2024
35. BASU A, Rais-Bahrami S
    Genomic risk scores in prostate cancer: polygenic yes, but are they poly-ancestral?
    J Natl Cancer Inst. 2024 Feb 16:djae025. doi: 10.1093.
    PubMed    
    
    
    
36. LAO Y, Guan X, Wang J, Bai Y, et al
    RE: Risks of depression, anxiety, and suicide in partners of men with prostate cancer: a national cohort study.
    J Natl Cancer Inst. 2024 Feb 12:djae032. doi: 10.1093.
    PubMed    
    
    
    January 2024
37. LEE KM, Nelson T, Bryant A, Teerlink C, et al
    Genetic risk and likelihood of prostate cancer detection on first biopsy by ancestry.
    J Natl Cancer Inst. 2024 Jan 11:djae002. doi: 10.1093.
    PubMed     Abstract available
    
    
    
38. WILKINSON S, Sowalsky AG
    Defining biology and recurrence risk in prostate cancers treated by neoadjuvant chemohormonal therapy.
    J Natl Cancer Inst. 2024;116:12-14.
    PubMed    
    
    
    
39. FEDELI U, Barbiellini Amidei C, Han X, Jemal A, et al
    Changes in cancer-related mortality during the COVID-19 pandemic in the United States.
    J Natl Cancer Inst. 2024;116:167-169.
    PubMed     Abstract available
    
    
    December 2023
40. CRUMP C, Stattin P, Brooks JD, Sundquist J, et al
    Risks of Depression, Anxiety, and Suicide in Partners of Men with Prostate Cancer: A National Cohort Study.
    J Natl Cancer Inst. 2023 Dec 7:djad257. doi: 10.1093.
    PubMed     Abstract available
    
    
    November 2023
41. FREEMAN JR, Saint-Maurice PF, Watts EL, Moore SC, et al
    Actigraphy-derived measures of sleep and risk of prostate cancer in the UK Biobank.
    J Natl Cancer Inst. 2023 Nov 28:djad210. doi: 10.1093.
    PubMed     Abstract available
    
    
    
42. COOPERBERG MR
    Can early prostate cancer screening help address mortality disparities among Black men?
    J Natl Cancer Inst. 2023 Nov 10:djad217. doi: 10.1093.
    PubMed    
    
    
    October 2023
43. HU S, Chang CP, Snyder J, Deshmukh V, et al
    Mental health outcomes in a population-based cohort of patients with prostate cancer.
    J Natl Cancer Inst. 2023 Oct 23:djad175. doi: 10.1093.
    PubMed     Abstract available
    
    
    
44. MA T, Jin L, Bai S, Liu Z, et al
    Loss of Feedback Regulation between FAM3B and Androgen Receptor Driving Prostate Cancer Progression.
    J Natl Cancer Inst. 2023 Oct 17:djad215. doi: 10.1093.
    PubMed     Abstract available
    
    
    September 2023
45. KENSLER KH, Johnson R, Morley F, Albrair M, et al
    Prostate Cancer Screening in African American Men: A Review of the Evidence.
    J Natl Cancer Inst. 2023 Sep 15:djad193. doi: 10.1093.
    PubMed     Abstract available
    
    
    
46. SUMIYOSHI T, Wang X, Warner EW, Sboner A, et al
    Molecular features of prostate cancer post-neoadjuvant therapy in the Phase 3 CALGB 90203 trial.
    J Natl Cancer Inst. 2023 Sep 7:djad184. doi: 10.1093.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge. Privacy / Datenschutzerklärung | Imprint / Impressum